

## Invitation to presentation of Cantargia's Year-End report 2024

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim October – December and Year-End report of 2024 at 3 pm (CET) on February 21, 2025. The report will be published at 07:00 am (CET) on the same day.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on February 21, at 3:00 pm (CET), where Cantargia's Interim CEO, Damian Marron, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: <https://cantargia.events.inderes.com/q4-report-2024>

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: <https://conference.inderes.com/teleconference/?id=5006304>

The webcast will also be available on demand on Cantargia's corporate website: [www.cantargia.com](http://www.cantargia.com)

### For further information, please contact

Damian Marron, Interim CEO

Telephone: +46 (0)46-275 62 60

E-mail: [damian.marron@cantargia.com](mailto:damian.marron@cantargia.com)

### About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at [www.cantargia.com](http://www.cantargia.com).



**PRESS RELEASE**

13 February 2025 08:00:00 CET

**Attachments**

**[Invitation to presentation of Cantargia's Year-End report 2024](#)**